Delivery of small mocluer drugs with Metal-Organic Cage-Based Microenvironment-Responsive Nanomedicine for Atherosclerosis theranostic

Motivation: Due to the complex pathogenesis of AS formation, the clinical treatment of AS with medicine is durable and often ineffective. it is necessary to seek a new strategy that is broadly applicable to all patients for AS theranostics . Goal(s): MM nanoparticles could delivering small molecule drugs to plaques and monitored by MR in real time upon Mn2+ released from AS microenvironment-responsive MnO2 nanoparticles. Approach: In vitro and vivo studies on 3.0T and 9.4T MR scaner. Results: In vitro and vivo studies showed that MM could be monitored by MR in real time upon Mn2+ released from acidic- and H2O2- microenvironment-responsive MnO2 nanoparticles. Impact: Nanocarriers(MM) exhibited remarkable in vivo MRI monitoring of the therapeutic process with a long imaging window and good biocompatibility and biosafety. This MRI-visible nanomedicine shows immense potential as a theranostic platform for AS therapy.